The American Cancer Society has updated its prostate cancer screening guidelines for the first time since 2010, recommending regular blood tests for millions of men in an effort to detect the disease earlier and reduce cancer-related deaths. The new recommendations, announced Thursday, November 12, 2026, represent a significant change in how doctors are encouraged to approach prostate cancer screening.
Under the updated guidelines, men at average risk of developing prostate cancer should receive a prostate-specific antigen, or PSA, blood test every two years between ages 50 and 69. Men considered at higher risk, including Black men and those with a strong family history of the disease, are advised to begin annual screening at age 45.
The recommendations replace the organization’s previous approach, which emphasized conversations between patients and their doctors about whether screening was appropriate rather than directly recommending routine testing.
The PSA test measures levels of prostate-specific antigen, a protein produced by both healthy and cancerous prostate cells. Elevated levels can indicate prostate cancer, although they do not necessarily mean a person has the disease. Other conditions, including an enlarged prostate, can increase PSA levels, and temporary changes may also occur following vigorous physical activity.
For years, concerns about the limitations of PSA testing influenced screening recommendations. Widespread testing sometimes resulted in unnecessary biopsies, additional medical procedures and treatment for slow-growing cancers that might never have caused serious health problems.
The American Cancer Society now says stronger scientific evidence supports regular screening because it can reduce deaths from prostate cancer and help identify dangerous tumors before they spread.
Advances in diagnostic testing and cancer management have also helped address some of the risks associated with earlier screening methods.
Rather than immediately recommending a biopsy whenever a PSA result is elevated, doctors can repeat the blood test to determine whether the increase persists. Magnetic resonance imaging, commonly known as MRI, and additional biomarker testing can then help determine whether further investigation is necessary.
For men ages 45 through 69, the updated guidance recommends repeating a PSA test when the initial result reaches 3.0 nanograms per milliliter or higher. For those ages 70 through 74, the threshold is 6.5 nanograms per milliliter. Follow-up testing is generally recommended within two weeks to three months.
If elevated PSA levels are confirmed, physicians can use the additional testing to help decide whether a biopsy is appropriate.
The guidelines also encourage active surveillance for patients diagnosed with low-risk prostate cancer. This approach involves monitoring the disease through regular medical evaluations rather than immediately beginning surgery, radiation or other aggressive treatments.
Active surveillance can help patients avoid complications from unnecessary treatment while allowing doctors to intervene if a tumor begins showing signs of becoming more dangerous.
Dr. Ash Tewari, who leads the urology department at the Icahn School of Medicine at Mount Sinai in New York, welcomed the updated recommendations. Although he was not involved in developing the guidelines, he said they provide greater clarity for primary care physicians who regularly discuss cancer screening with patients.
Tewari believes the more direct recommendations could encourage additional men to undergo testing and potentially prevent deaths through earlier detection.
The guidance also places particular emphasis on patients who face a greater likelihood of developing prostate cancer.
Black men are encouraged to undergo annual PSA screening from ages 45 through 69 because of their increased risk of developing and dying from the disease.
Men with a strong family history are also advised to follow that schedule. The American Cancer Society defines a strong family history as having a father, brother or son diagnosed with prostate cancer before age 65, or multiple first-degree relatives diagnosed at any age.
For non-Black men with only one first-degree relative diagnosed at age 65 or older, the organization recommends beginning screening at age 45 but continuing with testing every two years rather than annually.
Screening recommendations become more individualized as patients grow older.
For men ages 70 through 74, the American Cancer Society advises discussing the potential benefits and risks of continuing screening with a healthcare professional. At those ages, the advantages of detecting cancer early may be less certain, particularly when other medical conditions are present.
Routine screening is generally not recommended beginning at age 75. However, the guidelines acknowledge that some particularly healthy men between ages 75 and 79 may choose to continue testing after consulting their doctors, especially if previous PSA results have shown an upward trend.
The organization advises against screening for men ages 80 and older, as well as individuals of any age who are not expected to live at least another 10 years.
Despite the stronger recommendations, medical professionals emphasize that patients should continue discussing their individual circumstances with their doctors. Family history, age, overall health and personal preferences can all influence whether screening is appropriate.
The goal is to identify potentially life-threatening cancers while reducing the chances that patients undergo unnecessary procedures or treatment for tumors unlikely to cause harm.
Prostate cancer remains one of the most frequently diagnosed cancers among American men and is the second-leading cause of cancer-related deaths in men, behind lung cancer.
The American Cancer Society estimates that approximately 333,830 men in the United States will be diagnosed with prostate cancer in 2026, while an estimated 36,320 will die from the disease.
Although prostate cancer can be highly treatable when discovered before it spreads, advanced cases are more difficult to manage. Health officials believe clearer screening recommendations could help reduce the number of patients whose cancer is first identified at a later stage.
The updated guidance reflects years of research into screening effectiveness, diagnostic technology and treatment approaches. The American Cancer Society plans to continue monitoring new evidence and revise its recommendations as additional advances become available.
For men approaching the recommended screening ages, the changes provide a clearer starting point for conversations with healthcare providers about prostate cancer risk, testing and long-term health.



